

Review Article

New Concepts in Pacemaker Syndrome

D. Michael Farmer, MD, N. A. Mark Estes, III, MD, Mark S. Link, MD

Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts

Address for Correspondence: Mark S. Link, NEMC Box #197, Tufts-New England Medical Center
750 Washington Street, Boston, MA 02111. Email: Mlink@tufts-nemc.org

Abstract

After implantation of a permanent pacemaker, patients may experience severe symptoms of dyspnea, palpitations, malaise, and syncope resulting from pacemaker syndrome. Although pacemaker syndrome is most often ascribed to the loss of atrioventricular (A-V) synchrony, more recent data may also implicate left ventricular dysynchrony caused by right ventricular pacing. Previous studies have not shown reductions in mortality or stroke with rate-modulated dual-chamber (DDDR) pacing as compared to ventricular-based (VVI) pacing. The benefits in A-V sequential pacing with the DDDR mode are likely mitigated by the interventricular (V-V) dysynchrony imposed by the high percentage of ventricular pacing commonly seen in the DDDR mode. Programming DDDR pacemakers to encourage intrinsic A-V conduction and reduce right ventricular pacing will likely decrease heart failure and pacemaker syndrome. Studies are currently ongoing to address these questions.

Keywords: VVI = ventricular-based, VVIR = rate modulated ventricular-based, A-V = atrioventricular, V-V = interventricular, V-A = ventricular-atrial, LBBB = left bundle branch block, LVEF = left ventricular ejection fraction, DDDR = rate modulated dual-chamber, SND = sinus node dysfunction, AAI = single-chamber atrial, AF = atrial fibrillation, LV = left ventricular, RV = right ventricular

Introduction

Pacemaker syndrome consists of the cardiovascular signs and symptoms of heart failure and hypotension induced by right ventricular (RV) pacing. The reported incidence of pacemaker syndrome likely approaches 20% in rate modulated ventricular-based (VVIR) pacing¹. Over the last three decades the understanding of pacemaker syndrome has evolved. Initially described as only the sequela of A-V dysynchrony, pacemaker syndrome may be highly influenced by RV-left ventricular (LV) dysynchrony as well. The intricate interplay of these two factors along with autonomic and neurohormonal changes cause the compilation of symptoms known as the pacemaker syndrome.

Pacemaker Syndrome

Pacemaker syndrome was first described in 1969 by Mitsui et al. as a collection of symptoms associated with right ventricular pacing². Since its first discovery, there have been

many definitions of pacemaker syndrome, and the understanding of the cause of pacemaker syndrome is still under investigation. In a general sense, pacemaker syndrome can be defined as the symptoms associated with right ventricular pacing relieved with the return of A-V and V-V synchrony.

The symptoms of pacemaker syndrome included dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, hypotension, pre-syncope, and even syncope^{3,4,5}. Heart failure signs include elevated neck veins, rales, and pedal edema. Physical exam can often reveal cannon A-waves. This sign occurs secondary to ventricular-atrial (V-A) conduction and the contraction of the atria against closed A-V valves. Although relatively uncommon, syncope has been attributed to pacemaker syndrome. Syncope is usually associated with systolic blood pressure declines of greater than 20 mm Hg that can occur with the onset of pacing. Additional symptoms attributed to pacemaker syndrome include easy fatigability, malaise, headache, and the sensation of fullness and pulsations in the head and neck. Pacemaker syndrome is most severe when intact V-A conduction is present⁶. The elevated venous pressures associated with the contraction against closed A-V valves causes a vagal afferent response resulting in peripheral vasodilation and hypotension.

Incidence

The reported incidence of pacemaker syndrome has ranged from 2%⁷ to 83%⁸. The wide range of reported incidence is likely attributable to two factors. The first is the criteria used to define pacemaker syndrome. In the Pacemaker Selection in the Elderly (PASE) study, pacemaker syndrome was defined as symptoms severe enough to warrant reprogramming from ventricular to dual-chamber pacing⁹. The Mode Selection Trial (MOST) investigators defined pacemaker syndrome as occurring if either one of two different criteria occurred¹. The first criteria was new or worsened dyspnea, orthopnea, elevated jugular venous pressure, rales, and edema with ventricular (VA) conduction during ventricular pacing. The second criteria was symptoms of dizziness, weakness, presyncope, or syncope, and a >20 mm Hg reduction of systolic blood pressure when the patient had VVIR pacing compared with atrial pacing or sinus rhythm. The second factor in the wide range of reported incidence of pacemaker syndrome is the therapy used to resolve that diagnosis. When surgical revision is required to upgrade a patient from VVIR pacing, the incidence of pacemaker syndrome has been low. In the Canadian Trial of Physiologic Pacing (CTTOP), surgical revision was required for the change from VVIR to dual chamber pacing, and the incidence of pacemaker syndrome was reported to be 2.7% at three years¹⁰. In other pacemaker mode trials, patients were implanted with dual chamber devices and then either programmed to VVIR or DDDR pacing. In these studies, patients complaining of symptoms consistent with pacemaker syndrome could be easily upgraded to DDDR mode by simple pacemaker reprogramming. In the PASE and MOST studies in which devices could be reprogrammed from VVIR to DDDR mode, the incidence of pacemaker syndrome was higher than in those studies that required an invasive intervention to change pacing mode^{9,11}.

A-V vs. V-V dysynchrony

The majority of the symptoms of pacemaker syndrome are likely attributable to the reduction in cardiac output that is associated with right ventricular pacing^{3,4,5}. Several studies have demonstrated the hemodynamic superiority and increase in cardiac output of A-V sequential pacing over ventricular pacing¹². Other studies have shown that A-V and V-V synchrony are independent contributors to the hemodynamic ramifications of right ventricular pacing^{13,14}. Right ventricular pacing with or without A-V synchrony induces a physiologic contraction similar to that caused by left bundle branch block (LBBB). The effects of LBBB have been well studied. LBBB leads to an asynchronous ventricular contraction leading to **D**.

altered diastolic filling time, increase in mitral regurgitation, as well as a reduction in left ventricular ejection fraction (LVEF)^{15,16,17}. Thus, the reduction in cardiac output and symptoms associated with pacemaker syndrome are likely secondary to the loss of both A-V and V-V synchrony that is associated with right ventricular apical pacing¹⁸.

“Physiologic” vs. Ventricular pacing Trials

The physiologic benefits of A-V sequential have caused DDDR pacing to become common practice in most patients with sinus node dysfunction (SND). The results of completed randomized clinical trials of pacemaker mode selection have been somewhat conflicting. Overall, most trials have not shown reduction in heart failure, reduction in mortality, or improvement in quality of life with A-V sequential pacing (**Table 1**).

Table 1: Clinical Trials of Pacemaker Mode Selection

Trial	No. of Patients	Modes	Follow-up	Primary Endpoints	Results
Danish Mode Selection Trial	225	AAI vs. VVI	3.3 years, long term 5.5 years	Frequency of atrial fibrillation, thromboembolic events	Long term follow-up favored atrial pacing in all clinical endpoints including mortality
PASE	407	DDDR vs. VVIR	QOL eval at 3, 9, and 18 months	Quality of Life (QOL)	No difference in QOL in the two pacing modes. No differences in clinical outcomes between pacing modes. Subgroup analysis of SND pts. With trend toward benefit in QOL and AF in DDDR group
CTOPP	2568	DDDR or AAIR vs. VVIR	Average: 3 years	Stroke or death due to cardiovascular cause	No difference in stroke or death. Atrial Fibrillation less frequent in atrial-based pacing.
MOST	2010	DDDR vs. VVIR	Median: 33 months	Death and non-fatal stroke	No difference in death and non-fatal stroke. Heart failure hospitalization and atrial fibrillation less in DDDR group.
DANPACE	2000	AAI vs. DDD with short AV delay		Mortality	Ongoing
SAVE-PACE	1800	DDD with search AV hysteresis vs. DDD		Percentage of ventricular pacing, AF, and LV remodelling	Ongoing

In the first of such trials, Anderson et al. compared single-chamber atrial (AAI) with VVI pacing in 225 patients with SND, normal A-V conduction, and a narrow QRS who had standard pacing indications⁷. The primary endpoints were frequency of atrial fibrillation (AF) and thromboembolic events. The original study follow-up was 3.3 years with a subsequent analysis at 5.5 years. Long term follow-up demonstrated persistent reduction in the primary endpoints of AF, thromboembolic events, chronic AF, and all cause mortality in the AAI paced group. At longer follow-up, the VVI group had an increased incidence of heart failure, worsening echocardiographic measurements of LV function, and increase in all-cause mortality. These long-term results have not been reproduced by any other prospective, randomized trial comparing solely atrial-based to ventricular-based pacing, although the pacing mode in **D**.

subsequent trials was mainly DDDR.

In the PASE study, 407 patients older than 65 years of age, in sinus rhythm, who required a pacemaker for bradycardia, were randomized to VVIR or DDDR pacing⁹. The primary end point was quality-of-life. Secondary endpoints included death from all causes, first nonfatal stroke or death, first hospitalization for heart failure, development of atrial fibrillation, and the development of pacemaker syndrome. At quality of life evaluations at 3, 9 and 18 months, there were no differences between the two pacing modes. There was a 26% crossover rate due to the development of pacemaker syndrome. No differences in clinical outcomes were observed. There were some trends that showed benefit in clinical outcomes in the DDDR group, especially in the subset of patients with SND, but none were of statistical significance.

As a result of the conflicting data in the Anderson et al. trial and the PASE study, two larger trials in pacemaker mode selection were performed. In the Canadian Trial of Physiologic Pacing (CTOPP) trial, 2568 patients with symptomatic bradycardia requiring pacing were randomized to atrial-based (AAI, AAIR, DDD, or DDDR) or ventricular pacing (VVI or VVIR)¹⁰. AAI and AAIR combined for only 5% of the patients assigned to the atrial-based group. The remaining 95% in the atrial-based group were either DDD or DDDR paced. The combined endpoint of stroke or death due to cardiovascular causes after a 3-year follow-up was not different between the two groups. The secondary endpoints of AF and chronic AF were observed less commonly in the atrial-based group. After an eight year follow-up, there were no significant differences in death or stroke between the two groups¹⁹.

In the Mode Selection Trial in Sinus Node Dysfunction (MOST) study, 2020 patients with SND received dual chamber pacemakers and were randomized to either VVIR or DDDR pacing¹¹. The mean follow-up was 33 months and the primary endpoints were death and nonfatal stroke. There were no differences in the primary endpoint between the two groups. The incidence of atrial fibrillation was lower with dual-chamber pacing. Subsequent analyses of the MOST data, has shown that the benefits of A-V sequential pacing are likely attenuated by the ventricular pacing that occurs in the DDDR mode²⁰. Patients with a pre-paced QRS duration less than 120 ms were analyzed for percentage of ventricular pacing and clinical events. The percentage of ventricular pacing was determined from stored pacemaker data. The percentage of ventricular pacing was greater in the DDDR versus VVIR mode (90% vs. 58%). The percentage of ventricular pacing was a strong predictor of heart failure hospitalization in both pacing modes. The risk of AF increased linearly with percentage of ventricular pacing in both groups. The authors concluded that ventricular desynchronization imposed by ventricular pacing even when A-V synchrony is preserved increases the risk of heart failure hospitalization and AF in SND with normal baseline QRS duration. The analyses by Sweeney et al. illustrate the fact that DDDR and DDD pacing is not physiologic. The pacing mode that is most physiologic is AAI or AAIR. This fact can likely explain the discrepancies between the study by Anderson et al. and the subsequent studies in pacemaker mode selection. The benefit derived from A-V sequential pacing in the CTOPP and MOST studies was likely counterbalanced by the detrimental effects of right ventricular pacing seen in the DDDR mode.

Several ongoing trials are looking at the benefits of reduction in RV pacing in the DDDR mode. The first is the Danish Multicenter Randomized Study of Atrial Inhibited Versus Dual-Chamber Pacing in Sick Sinus Syndrome (DANPACE). This trial is comparing AAI pacing and DDDR pacing with a short A-V delay. The second is the Search A-V Extension for Promoting Atrioventricular Conduction (SAVE-PACE) study. This study will evaluate the use of search hysteresis, a pacemaker feature that allows the extension of the A-V delay to reduce right ventricular pacing. The study investigators hypothesize that the reduction in RV pacing will lead to a reduction in left ventricular remodeling and AF.

Conclusion

Pacemaker syndrome is a common problem faced by clinicians who implant pacemakers

and for those who take care of these patients. The syndrome is likely caused by both the loss of A-V and V-V synchrony imposed by right ventricular pacing. The studies on pacemaker mode selection have shown a high incidence of pacemaker syndrome. Because of the high incidence of pacemaker syndrome in VVIR-paced patients, atrial-based pacing is preferred.

These studies have also showed that DDDR pacing as compared to VVIR pacing decreases the incidence of AF, but does not affect stroke or mortality. The percentage of beats ventricular paced in these studies in patients who received dual-chamber pacemakers is likely to influence the incidence of pacemaker syndrome and heart failure. The amount of ventricular pacing in the DDDR mode is dependent on spontaneous A-V conduction and programmed A-V delay. Optimal programming should seek to reduce ventricular pacing. The reduction in the percentage of RV pacing in dual-chamber pacing modes will likely reduce the incidence of pacemaker syndrome, heart failure, and possibly mortality.

References

1. Link MS, Hellkamp AS, Estes NAM, et al. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST), JACC, Vol. 43, No. 11, 2004: 2066-2071.
2. Mitsui T, Hori M, Suma K, Wanibuchi Y, Saigusa M. The “pacemaking syndrome.” In: Jacobs JE, ed. Proceedings of the Eighth Annual International Conference on Medical and Biological Engineering. Chicago, Ill: Association for the Advancement of Medical Instrumentation; 1969:29-33.
3. Ellenbogen KA, Gilligan DM, Wood MA, Morillo C, Barold SS. The pacemaker syndrome- a matter of definition. Am J Cardiol 1997;79:1226-9.
4. Ausubel K, Furman S. The pacemaker syndrome. Ann Intern Med 1985;103:420-9.
5. Furman S. Pacemaker Syndrome. Pacing Clin Electrophysiology 1994;17:1-5.
6. Ellenbogen, KA, Wood MA. Cardiac Pacing and ICDs. 3rd Edition: 149-150.
7. Anderson HR, Thuesen L, Bagger JP, Vesturlund T, Thomsen PEB. Prospective randomized trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet 1994; 344:1523-8.
8. Heldman D., Mulvihill D, Nguyen H, et al. True incidence of pacemaker syndrome. Pacing Clin Electrophysiol 1990;13:1742-50.
9. Lamas GA, Orav EJ, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared to dual chamber- pacing. N Engl J Med 1998;338:1097-104.
10. Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke or death due to cardiovascular causes. N Engl J Med 2000;342:1385-91.
11. Lamas GA, Lee KL, Sweeney MO et al. Ventricular pacing or dual chamber pacing for sinus node dysfunction. N Engl J Med 2002;346:1854-62
12. Lamas, GA. Physiological consequences of normal atrioventricular conduction: applicability to modern cardiac pacing. J Card Surg. 1989;4:89-98.

13. Zile MR, Blaustein AS, Shimizu G, et al. Right ventricular pacing reduces the rate of left ventricular relaxation and filling. *J Am Coll Cardiol.* 1987;10:702-709.
14. Burkhoff D, Oikawa RY, Sagawa K. Influence of pacing site on canine left ventricular contraction. *Am J Physiol.* 1986;251:H428-H435.
15. Grines CL, Bashore TM, Boudoulas H, et al. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. *Circulation.* 1989; 79:845-53.
16. Rosenqvist M, Isaz K, Botvinivk EH, et al. Relative importance of activation sequence compared to atrioventricular synchrony in left ventricular function. *Am J Cardiol.* 1991;67:148-156.
17. Mark JB, Chetman PM. Ventricular pacing can induce hemodynamically significant mitral valve regurgitation. *Anesthesiology.* 1991;74:375-377.
18. Lamas GA, Ellenbogen KA. Evidence Base for Pacemaker Mode Selection: From Physiology to Randomized Trials. *Circulation* 2004;109:443-451.
19. Kerr CR, Connolly SJ, Abdullah HM, Roberts RS, et al. Canadian Trial of Physiological Pacing during long term follow-up. *Circulation.* 2004; 109(3):357-62.
20. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation.* 2003;107:2932-2937.